Markets Stocks Economy Crypto Earnings Banking Energy
Home› Stocks› Feature
Stocks · Exclusive

RBC Sees Kraft Heinz Turnaround, But Payoff Delayed to 2027

RBC Sees Kraft Heinz Turnaround, But Payoff Delayed to 2027
Stocks · 2026
Photo · Marcus Devlin for Daily Digest Invest
By Marcus Devlin Equities Correspondent Oct 23, 2026 3 min read

Kraft Heinz may be slowly winning back shoppers, but investors shouldn't expect a quick payoff. That's the takeaway from a Friday note by RBC Capital Markets, which sees improving market-share trends across parts of the food giant's portfolio—yet cautions that most of the financial benefits are likely years away.

The bank pointed to the company's meats business as the clearest sign of progress. Over the latest four weeks, Kraft Heinz's share decline in that category narrowed to 29 basis points, compared with a 107-basis-point drop over the past 52 weeks. In plain terms, the slide is slowing—a possible early signal that the company's efforts to win back customers are starting to work.

Mixed picture elsewhere

Beyond meats, RBC described share trends across eight other categories as mixed. But it noted that volume trends look better, which matters because it suggests demand is stabilizing even before pricing and product mix translate into market-share gains. In other words, the company may be selling more units even if its slice of the overall pie isn't growing yet.

Still, not everything is rosy. RBC called out refreshment beverages, frozen meals and sides, refrigerated snacks, and cheese as the weakest spots. These are categories where Kraft Heinz continues to lose ground, and they could weigh on overall performance in the near term.

The bank argued that while improvements are “evident,” “the bulk” of the benefits likely arrive in 2027 and beyond. That's a long wait for investors who are used to seeing results within a few quarters.

What it means for investors

RBC kept its outperform rating and $32 price target on Kraft Heinz shares, which were trading around $24.76 at the time of the report. That implies meaningful upside from current levels—but the timeline is stretched.

When an analyst says most of the upside sits years out, it's a reminder that this is a long-duration turnaround. The story depends more on what Kraft Heinz can earn in 2027-2028 than on the next couple of quarters. Markets usually lean hardest on the next 12-18 months of earnings and cash flow, and profits that arrive later tend to matter less today because investors discount the future.

So even if market share keeps improving now, it may not lead to big near-term earnings upgrades or a higher valuation multiple until those forward-year forecasts start moving meaningfully. That's why the path to RBC's $32 target can hinge less on next-quarter execution and more on whether estimates for 2027 and 2028 get revised up—and until then, the stock can stay range-bound around the mid-$20s.

For everyday investors, this is a classic case of a turnaround story that requires patience. The company is making progress, but the payoff is likely to be gradual. If you're considering Kraft Heinz, it's worth asking whether you're comfortable waiting several years for the full benefit to show up in the stock price.

In the broader market, analysts often adjust price targets based on near-term catalysts. When they push the timeline out, it can signal that the company's recovery is real but slow. That's exactly what RBC is saying about Kraft Heinz.

Investors will likely watch upcoming quarterly results for signs that the improving trends are broadening beyond meats. If volume gains continue and the weakest categories start to stabilize, that could bring forward some of the expected benefits. But for now, RBC's message is clear: this is a marathon, not a sprint.

More from this story

Next article · Don't miss

UBS: Medpace's 2027 outlook too cautious as bookings, pipeline grow

UBS thinks Medpace's 2027 guidance is too cautious, citing strong bookings and a growing pipeline. The bank raised its price target to $700, but flags $20 million in added costs from a Cincinnati expansion.

Read the story →
UBS: Medpace's 2027 outlook too cautious as bookings, pipeline grow